Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05293522 · ClinicalTrials.gov registry record · Phase 2
A Study of NTX-001 in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair.
A Phase 2 study, sponsored by Neuraptive Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT05293522: Clinical Trial Phase 2 study, sponsored by Neuraptive Therapeutics.
NCT05293522 is a Phase 2 study that was terminated before completion, run by Neuraptive Therapeutics. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05293522, a Phase 2 study, was terminated before completion, sponsored by Neuraptive Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study involves the use of an Investigational Product called NTX-001. It is a product used in the repair of nerve injuries. It is used in the operating room. The main purposes of this study are to 1) see how safe NTX-001 is when used in nerve repair and, 2) see if your nerve becomes functional in a shorter period of time when compared to what is normally done to treat nerve injuries.
Primary Outcome
Measuring the safety of NTX-001 following the nerve repair based on the number of reported adverse events.
Interventions
- COMBINATION_PRODUCT NTX-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-07-12 |
| Est. Completion | 2023-08-22 |
| Phase | Phase 2 |
Why NCT05293522 stopped before completion
NCT05293522 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which NTX-001 is the first listed.
NCT05293522 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05293522 about?
NCT05293522 is a clinical study titled "A Study of NTX-001 in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair.". This study involves the use of an Investigational Product called NTX-001. It is a product used in the repair of nerve injuries. It is used in the operating room. The main purposes of this study are to 1) see how safe NTX-001 is when used in nerve repair and, 2) see if your nerve becomes functional i...
What is the current status of trial NCT05293522?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2022-07-12. Estimated completion is 2023-08-22.
What interventions are being tested in trial NCT05293522?
The interventions under investigation include: NTX-001 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05293522?
This trial is sponsored by Neuraptive Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05293522's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI